Yi X - Search Results

1

RNA m⁶A modification in prostate cancer: A new weapon for its diagnosis and therapy.

Han Z, Yi X, Li J, Zhang T, Liao D, You J, Ai J. Han Z, et al. Among authors: yi x. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188961. doi: 10.1016/j.bbcan.2023.188961. Epub 2023 Jul 26. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37507057 Review.

2

Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation.

Zheng X, Xu H, Gong L, Cao D, Jin T, Wang Y, Pi J, Yang Y, Yi X, Liao D, Jin X, Wei Q, Yang L, Li H, Ai J. Zheng X, et al. Among authors: yi x. Prostate. 2021 May;81(6):347-356. doi: 10.1002/pros.24113. Epub 2021 Mar 12. Prostate. 2021. PMID: 33710645

3

Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.

Xiong X, Qiu S, Yi X, Xu H, Liao D, Lei H, Bai S, Peng G, Ai J, Yang L. Xiong X, et al. Among authors: yi x. Urol Oncol. 2021 Nov;39(11):754-763. doi: 10.1016/j.urolonc.2021.06.012. Epub 2021 Jul 28. Urol Oncol. 2021. PMID: 34330654

4

Preparation and characterization of a polyclonal antibody against PTEN-Long.

Yi X, Wang Z, Xiong X, Zheng X, Peng G, Xu H, Wei Q, Li H, Zhu Y, Ai J. Yi X, et al. Biotechnol Appl Biochem. 2022 Aug;69(4):1622-1632. doi: 10.1002/bab.2232. Epub 2021 Aug 22. Biotechnol Appl Biochem. 2022. PMID: 34338347

5

Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.

Xiong X, Qiu S, Yi X, Xu H, Lei H, Liao D, Bai S, Peng G, Wei Q, Ai J, Yang L. Xiong X, et al. Among authors: yi x. Urol Oncol. 2022 Jan;40(1):4.e19-4.e28. doi: 10.1016/j.urolonc.2021.08.014. Epub 2021 Sep 20. Urol Oncol. 2022. PMID: 34548234

6

Comparison of the Efficacy and Safety of Extracorporeal Shock Wave Lithotripsy and Flexible Ureteroscopy for Treatment of Urolithiasis in Horseshoe Kidney Patients: A Systematic Review and Meta-Analysis.

Yi X, Cao D, You P, Xiong X, Zheng X, Jin T, Peng G, Xu H, Liao D, Wei Q, Li H, Yang L, Ai J. Yi X, et al. Front Surg. 2021 Oct 25;8:726233. doi: 10.3389/fsurg.2021.726233. eCollection 2021. Front Surg. 2021. PMID: 34760915 Free PMC article.

7

Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.

Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei Q, Li H, Ai J. Xu H, et al. Among authors: yi x. Mol Cancer. 2021 Dec 6;20(1):159. doi: 10.1186/s12943-021-01465-w. Mol Cancer. 2021. PMID: 34872567 Free PMC article.

8

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.

Zheng X, Xu H, Yi X, Zhang T, Wei Q, Li H, Ai J. Zheng X, et al. Among authors: yi x. Mol Cancer. 2021 Dec 6;20(1):160. doi: 10.1186/s12943-021-01452-1. Mol Cancer. 2021. PMID: 34872584 Free PMC article.

9

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence.

Yi XY, Cao DH, You PH, Xiong XY, Zheng XN, Peng G, Liao DZ, Li H, Yang L, Ai JZ. Yi XY, et al. Asian J Androl. 2022 Mar-Apr;24(2):180-185. doi: 10.4103/aja202188. Asian J Androl. 2022. PMID: 34975068 Free PMC article.

10

Phthalate exposure enhances incidence of urinary incontinence: US NHANES, 2003-2004 and 2005-2006.

Yi X, Jin K, Qiu S, Xiong X, Zhang T, Peng G, Liao D, Zheng X, Xu H, Li H, Yang L, Wei Q, Ai J. Yi X, et al. Environ Sci Pollut Res Int. 2022 Sep;29(43):64692-64703. doi: 10.1007/s11356-022-20307-w. Epub 2022 Apr 27. Environ Sci Pollut Res Int. 2022. PMID: 35474427

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,732 results

Search Page

Filters